Ann: BodyGuard Program Update , page-35

Hi greenhouse,

"A portion of our R&D activities is conducted through joint ventures... Teva Global R&D is currently creating the infrastructure for the development of new therapeutic entities (NTEs), which are known molecules that are formulated, delivered or used in a novel way to address unmet patient needs. To date, several NTEs have been internally approved for development and additional NTE candidates have been identified and are currently under assessment."

Nice!

I'm sure that you will already be well aware of OBJ's ability to enhance the delivery of anti-cancer drug 5-aminolevulinic acid - and if you are you will undoubtedly also be aware that the enhanced levels achieved using OBJ's technology have been quite stunning, and increasingly so, over the past 7-8 years...

Enhanced sonophoretic delivery of 5-aminolevulinic acid
Krishnan G, Grice JE, Roberts MS, Benson HA, Prow TW.
Curtin Health Innovation Research Institute, School of Pharmacy, Curtin University, Perth, WA, Australia.

Abstract
BACKGROUND/AIMS:
5-Aminolevulinate (ALA) is an important photodynamic therapy drug for the treatment of actinic keratoses and other non-melanoma skin cancers in cosmetically sensitive areas. One limitation of this drug is a relatively high recurrence rate. Our aim was to evaluate the feasibility of ultrasound augmented ALA delivery in excised human skin.
MATERIALS AND METHODS:
An ultrasonic delivery device was used to enhance radiolabelled ALA into excised skin. Quantification of ALA was performed after passive and ultrasonic ALA delivery. Transepidermal water loss was used as a measure of barrier function before and after ultrasonic treatment.
RESULTS:
We found that ultrasonic treatment dramatically increased the mean cumulative amount of ALA to P< 0.0001 from 4 to 8 h when compared to passive ALA treatment. The flux was calculated to be 54.8 ± 8.0 µg/cm(2) h with ultrasound treatment. TEWL increased nearly two-fold, from 12.3 to 21.0, after ultrasound treatment.
CONCLUSION:
Our study supports the use of ultrasound for improved ALA delivery by showing significant improvements in the cumulative drug load and flux via combined ultrasound and ALA treatment. - Enhanced sonophoretic delivery of 5-aminolevulinic acid: preliminary human ex vivo permeation data
____________________

Another example of miniaturized ultrasonic innovation making some 'waves' is the Signos RT - the world's first 'personal' ultrasound device for non-invasive imaging of the human body intended for a number of clinical applications including musculo-skeletal indications - developed by Signostics Limited in Sth Australia, which have just received the green light for its FDA - 510(k) Application.

Handheld ultrasound device from Signostics receives 510K clearance from the FDA
Published on May 7, 2013
Handheld ultrasound device manufacturer Signostics has received a major boost with 510(k) clearance from the US Food and Drug Administration (FDA) to market its new Signos RT to the lucrative American market. 510(k) clearance from the FDA means the widely acclaimed Signos RT can now be sold throughout the US where it will be marketed as the “Sonimage P3” – the brand name of Signostics’ newly appointed global partner Konica Minolta Inc.

“FDA clearance for the USA market further enhances the potential of this innovative product and will enable medical practitioners and patients throughout America to benefit from the real-time point-of-care imaging capabilities that the device provides,” said Signostics’ Chief Executive Officer Warren Ortmann.

The Signos RT / Sonimage P3 device features unique patented technology and an award winning design to provide a lightweight handheld ultrasound device for high quality imaging at the point-of-care for medical practitioners, healthcare professionals and veterinarians globally across a broad range of clinical settings. - Source
____________________

In regards to yesterday's news advising about the appointment of the Lead Manager to manage the Placement of the Shortfall, sometimes it's worth looking past the 'eyes' of a stockbroker, and having a closer look at other fields of interest that he may be involved in...

We all understand how stockbrokers like to make a quick buck, but the following information should make one stop and consider whether this guy is really going to be interested in the quick p&d... or whether he may actually have the qualifications to understand that bigger opportunities lay ahead?

Alan Young AM
Co-Founder and Joint Managing Director

Prior to co-founding Baker Young some 25 years ago, Alan was one of Australia’s leading Fund Managers at National Mutual (now AXA), managing some of the companies best performing Investment Portfolios in Australia for several years.

In his twenties Alan entered Stockbroking and became both a member of the Australian Stock Exchange and co-founder/co-owner with David Baker of his own Stockbroking business. He is a leader in his field and is one of the most informed and innovative Stockbrokers in Australia.

2009 Queen's Birthday Honours: Awarded Order of Australia as a Member in the General Division for service to the community, particularly through business advisory roles with health, medical research and educational organisations.

Alan also has the current appointments

Chairman, Flinders Medical Centre Foundation, funding Medical Research, patient care and teaching at one of South Australia's largest co-located public hospital's and university;

Chairman, Flinders - Bio-Medical Enterprises Pty Ltd, South Australia's newest bioscience company targeting Asia, designing and building new biomedical devices and teaching hospitals how to use them both here and overseas;

Co- Author, Shine Young Report, A review of Health and Medical Research in South Australia commissioned by the South Australian Government, authored by Alan Young and Professor John Shine AO, CEO Garvan Institute, Sydney. The South Australian Government accepted the recommendation to establish a new flagship Health and Medical Research Institute and subsequently received a grant of $200 million out of the 2009 federal budget to establish the new Institute.

Vice Chairman of the South Australian Health & Medical Research Institute, which is the Flagship Institute for health and medical research in South Australia; a $200 Million headquarters is under construction and will house over 700 researchers.

Director of Signostics Ltd which is South Australian based, International Medical Device Company with a vision to be the Global Leader in providing clinicians with affordable handheld tools for use at the point-of-care.

Signos RT General Brochure

It's one thing for a stockbroker to be Awarded Order of Australia for his advisory service roles related to health and medical research, but Mr Young's experience suggests that he may also have quite a very good understanding for OBJ technology offerings...

Of course we can only speculate as much - The one thing we do know for sure is that Mr Young's Stockbroking firm appear keen to place our shortfall at a + 36.36% premium to the current sp :)

Struggling to see the downside it that - our market is a funny beast.